The veteran crew at Medicxi is back with a new $400M fund and an upbeat assessment of what's coming
No two biotech VC groups are exactly the same.
Each has its own specialty; each has its ideas about assets and platforms. And you can certainly place the experienced crew at Medicxi in the asset wing — with a special set of relationships with the top scientists in their own European sphere of influence in the startup world.
And now they have a new $400 million fund to keep going in exactly the same direction.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.